MCK Q1 Earnings Call: Product Mix Shifts, Portfolio Moves, and Strategic Acquisitions Highlight Quarter

Healthcare distributor and services company McKesson (NYSE:MCK) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 18.9% year on year to $90.82 billion. Its non-GAAP profit of $10.12 per share was 3% above analysts’ consensus estimates.

Is now the time to buy MCK? Find out in our full research report (it’s free).

StockStory’s Take

McKesson’s latest quarter was influenced by ongoing execution in its U.S. pharmaceutical distribution and specialty businesses, alongside targeted cost reductions and portfolio adjustments. Management emphasized the importance of onboarding new strategic customers and highlighted double-digit growth in volumes from retail national accounts and specialty products, particularly within oncology. CEO Brian Tyler noted, “We saw broad-based strength across the segment and stable market fundamentals, including solid pharmaceutical utilization trends.” The company’s prescription technology segment also delivered a strong showing, with increased demand for access and affordability solutions, supported by technology-driven operational efficiencies.

Looking ahead, management expects continued momentum to be driven by expansion in oncology and biopharma services, as well as contributions from recent acquisitions like PRISM Vision and the pending Core Ventures deal. The company’s guidance reflects confidence in its ability to sustain growth, with CFO Britt Vitalone stating, “We anticipate continued momentum in our core pharmaceutical distribution business, powered by the growth of specialty products, including continued growth in the distribution of specialty products to community providers.” Management also acknowledged external risks, such as potential policy changes and tariffs, but believes its diversified sourcing and operational flexibility position McKesson to manage these uncertainties.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong execution in specialty distribution, targeted acquisitions, and operational efficiencies, while noting the effects of recent divestitures and shifting product mix.

• Specialty and Oncology Expansion: Growth in specialty distribution, especially oncology, was fueled by onboarding new practices and integrating upcoming acquisitions, such as PRISM Vision and Core Ventures. Management highlighted that the U.S. Oncology Network now serves over 2,700 providers and expects this platform to be expanded further.
• Prescription Technology Solutions Momentum: The prescription technology segment delivered double-digit operating profit growth, driven by strong demand for access and affordability solutions. The company’s CoverMyMeds virtual assistant automated more than 20% of patient support center chats, maintaining customer satisfaction while improving efficiency.
• Medical Surgical Segment Realignment: The segment saw operational improvements from cost optimization initiatives, resulting in approximately $100 million in savings during the second half of the year. Management announced plans to separate the medical surgical business into an independent company to enhance strategic focus and value.
• Operational Efficiencies and Divestitures: Cost reductions were also achieved through recent divestitures, such as the sale of Rexall and Well.ca in Canada, which contributed to lower operating expenses. These actions were part of a broader portfolio management strategy to focus resources on higher-growth areas.
• Stable Market Fundamentals: Management reported solid pharmaceutical utilization trends and customer demand in core markets, particularly within the U.S. segment, while acknowledging that illness season severity levels and primary care volumes in the medical surgical segment varied compared to prior years.

Drivers of Future Performance

Management’s outlook for the coming quarters centers on specialty product growth, digital platform expansion, and strategic portfolio moves, amid an evolving policy and macroeconomic landscape.

• Oncology and Biopharma Growth: The addition of new providers to the U.S. Oncology Network and the integration of PRISM Vision and Core Ventures acquisitions are expected to drive specialty volume growth and enhance McKesson’s platform in high-value therapeutic areas. These moves are anticipated to contribute 6%-7% to operating profit growth in the U.S. pharmaceutical segment.
• Prescription Technology Investments: Continued investment in digital access solutions and automation—such as enhanced prior authorization capabilities—aims to support expanding demand from biopharma manufacturers and payers. Management highlighted that GLP-1 medications and new brands will sustain growth in prescription technology, but noted that third-party logistics volumes may grow at a slower rate than in the prior year.
• Policy, Tariff, and Regulatory Uncertainties: Executives flagged potential changes in drug pricing policy (such as Medicare Part B reforms) and tariffs as risk factors. However, management believes diversified sourcing strategies and flexibility in pricing should limit the negative impact under current assumptions.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the successful integration and performance of PRISM Vision and Core Ventures within the specialty and oncology networks, (2) updates on the planned separation of the medical surgical segment and its impact on strategic focus, and (3) sustained growth in prescription technology solutions, particularly as GLP-1 medication dynamics and payer policies evolve. Execution on digital platform investments and response to potential regulatory shifts will also be closely watched.

McKesson currently trades at a forward P/E ratio of 19.2×. In the wake of earnings, is it a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.